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OGAa b s t r a c t
Aggregation of tau into paired helical ﬁlaments is a pathological process leading to neurotoxicity in
Alzheimer’s disease and other tauopathies. Tau is posttranslationally modiﬁed by O-linked N-acetyl-
glucosamine (O-GlcNAc), and increasing tau O-GlcNAcylation may protect against its aggregation.
Research tools to study the relationship between tau aggregation and tau O-GlcNAcylation have
not been widely available. Here we describe the generation of a rabbit monoclonal antibody speciﬁc
for tau O-GlcNAcylated at Ser400 (O-tau(S400)). We show the utility of this antibody for in vitro and
in vivo experiments to investigate the function of O-GlcNAc modiﬁcations of tau at Ser400.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Tau is a component of the neuronal cytoskeleton where it is pri-
marily associated with axonal microtubules [1]. In Alzheimer’s dis-
ease and other tauopathies tau is aberrantly aggregated in
neuronal cell somata, which may be causative in the neurodegen-
erative process during the disease course [1]. Recent evidence sug-
gests that tau aggregation may be attenuated by increasing protein
O-GlcNAcylation in brain [2] and thus modifying this mechanism
may be a potential therapeutic approach to Alzheimer’s disease
and other tauopathies.
O-GlcNAcylation is a dynamic process in which proteins be-
come posttranslationally modiﬁed through the attachment of N-
acetyl-D-glucosamine (GlcNAc) moieties to the hydroxyl group ofserine and threonine residues [3]. The attachment of GlcNAc is cat-
alyzed by the enzyme O-GlcNAc transferase (OGT), which utilizes
uridine 50-diphospho-N-acetylglucosamine produced in the hexos-
amine biosynthesis pathway from glucose as substrate. Reversely,
O-GlcNAc moieties are enzymatically removed from proteins by
the glycoside hydrolase O-GlcNAcase (OGA) [4]. O-GlcNAcylation
often occurs at or near amino acid residues that can be phosphor-
ylated and thus it has been implied that O-GlcNAcylation can di-
rectly regulate phosphorylation of proteins.
Tau is subject to O-GlcNAcylation at several serine and threo-
nine residues including Thr123, Ser 208, Ser356, Ser400 and either
Ser409, 412, or 413 [5–7,2,8]. Ser400 is located within a cluster of
phosphorylation sites (Ser396, Ser400, Ser404, Ser409, Ser412,
Ser413, Ser416, and Ser422) at the C-terminal end of tau, several
of which have been implicated in tau pathology [9]. Ser400 appears
to play a predominant role in regulating the aggregation propen-
sity of tau as a S400A mutation in a recombinant O-GlcNAcylated
tau peptide abolished the aggregation attenuating effect on tau
that was observed for the wild type O-GlcNAcylated version of
the same peptide in vitro [2]. It is thus important to understand
the regulation of tau O-GlcNAcylation at this particular site, but
to date studies have been greatly hampered by the unavailability
of O-GlcNAc tau site-speciﬁc antibodies.
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bit monoclonal antibody, named Otau(S400), speciﬁc for tau O-Glc-
NAcylated at Ser400. We demonstrate the utility of this antibody
for biochemical applications in cells and tau transgenic mouse
models. This important research tool will readily allow the study
of tau O-GlcNAcylation and its implication for tau pathology
in vitro and in vivo and will greatly facilitate the discovery of
agents modifying tau O-GlcNAcylation at Ser400.
2. Material and methods
2.1. Generation of Otau(S400) antibody
The Otau(S400) antibody was generated at Epitomics, Inc.. In
brief, two peptides, O-GlcNAc tau (cVYKSPVV-(O-GlcNAc)S-
GDTSPRH) and unglycosylated tau (cVYKSPVVSGDTSPRH) were
synthesized to 90% purity and conjugated to four different carrier
proteins, KLH, OVA, Blue-Carrier, and BSA. Four three months old
New Zealand Whites rabbits were immunized with KLH- or OVA-
conjugated O-GlcNAc tau peptide employing a protocol of ﬁve sub-
cutaneous injections and two test bleeds per rabbit. Serum titers
against the BSA-conjugated O-GlcNAc tau and unglycosylated tau
peptides indicated that all rabbits demonstrated a good immune
response against the antigen (OD >0.3 at 1:64000 dilution). One
rabbit was chosen for a ﬁnal iv boost with Blue Carrier-conjugated
O-GlcNAc tau peptide, followed by splenocyte collection for
hybridoma fusion.>30 positive hybridoma clones were identiﬁed
by ELISA against the BSA-conjugated O-GlcNAc tau peptide and
subsequently counter-screened against BSA-conjugated unglyco-
sylated tau peptide. Three clones were selected for subcloning by
limited dilution. Ten subclones of each clone were selected based
on ELISA screening against BSA-conjugated O-GlcNAc and unglyco-
sylated tau peptides. One subclone was expanded and adapted to
production medium and subjected to endotoxin-free protein A
puriﬁcation.
2.2. Antigen binding afﬁnity ELISA
ELISA plates were coated with 50 ll/well of 1 lg/ml of BSA con-
jugated O-GlcNAc tau or unglycosylated tau peptide in bicarbonate
coating buffer overnight at 4 C. Antigen coated plates were
blocked with 100 ll/well of 1% BSA (9048–46-8, Amersco) in TBS
for 1 h at 37 C, followed by thorough washes in TBST. Starting
from 10 lg/ml 50 ll of 10-fold serial dilutions of the Otau(S400)
antibody prepared in TBS containing 1% BSA were added to the ELI-
SA plate and incubated for 1 h at 37 C. After three washes in TBST
anti-rabbit IgG conjugated with alkaline phosphatase (111–055-
003, Jackson ImmunoResearch) was added at a dilution of 1:1000
and incubated for 30 min at 37 C, washed again three times in
TBST and developed by adding 50 ll PNPP substrate (4264–83-9,
Amersco) freshly prepared in PNPP DEA buffer (34064, Pierce) for
15 min at RT before stopping with 50 ll 1 N NaOH. Absorbance
was read at OD 405 nm. EC50s were calculated using GraphPad
Prism software.
2.3. Plasmid cloning
The mammalian expression vector for myc-DDK tagged tau var-
iant 2 (TrueORFGold expression validated cDNA clone RC213312;
accession No. NM_005910.3) was obtained from OriGene. To gen-
erate tau-CGFP expression plasmids tau cDNA was transferred
from the myc-DDK-tau expression vector to the destination vector
pCMV6-AC-mGFP (PS100048, OriGene) following OriGene’s Rapid-
Shuttling Kit protocol. The human OGT cDNA was cloned from the
OGT/pENTR221 vector (IOH27987, Invitrogen) into the pDEST26destination vector (11809–019, Invitrogen) employing Gateway
cloning technology (Invitrogen).
2.4. Transfection, ThiametG treatment and lysis of cells
To generate stable tau-expressing cell lines HEK293 cells (CRL-
1573, ATCC) were transfected with myc-DDK-tau or tau-CGFP
cDNA via Lipofectamine 2000 (11668–019, Invitrogen) lipofection
according to the manufacturer’s protocol. Transfected cells were
cultured in MEM (11095, Invitrogen) containing 10% FBS (10099,
Invitrogen) and penicillin/streptomycin (15140, Invitrogen) for
16 h after which cells were transferred to 6-well plates and cul-
tured in the presence of 200 lg/ml geneticin (10131–027, Invitro-
gen) to 80% conﬂuency. Cells were subsequently plated at a density
of 1 cell/well in a 96-well plate and cultured until conﬂuent. Indi-
vidual clones were isolated and consecutively transferred into 24-
and 6-well plates for expansion. Tau expressing clones were con-
ﬁrmed by Western blotting with the tau-5 antibody. For OGT/tau
co-expression experiments OGT/pDEST26 cDNA was transfected
in HEK293 cells stably expressing myc-DDK-tagged tau via Lipo-
fectamine 2000 according to the manufacturer’s protocol. Mock
transfected HEKtau cells were used for control. For pharmacologi-
cal inhibition of OGA, HEKtau or HEK293 cells were treated with
either 10 lM ThiametG (MD08856, Carbosynth, UK) in 0.1% DMSO
or 0.1% DMSO alone and incubated for 16 h at 37 C. Cells from
transfection or ThiametG treatment experiments were lysed in
10 mM Tris–HCl (T1080, Teknova), pH 7.5, 1% SDS (24730, Invitro-
gen), EDTA-free protease inhibitors (04693159001, Roche) and
sonicated for 10 s, followed by incubation on ice for 10 min. Ly-
sates were centrifuged at 1000 g for 3 min and the ensuing super-
natants analyzed using the BCA protein assay kit (23227, Pierce)
according to the manufacturer’s protocol. 20–30 lg of protein ly-
sate were applied for Western blot analysis.
2.5. Puriﬁcation of O-GlcNAc tau from cell lysate
HEKtau cells were transiently transfected with OGT/pDEST26 as
described above. Mock transfected HEKtau cells were used for con-
trol. After 24 h of expression cells were lysed and tau protein was iso-
lated employing the Sigma FLAG Immunoprecipitation kit (FLAGIPT1,
Sigma) following the manufacturer’s instructions. Immunoprecipi-
tated tau protein was eluted from the FLAG beads with 100 mM gly-
cine, pH 2.0 and immediately dialyzed into PBS. Two micrograms of
eluate was subjected to Western blotting as described below.
2.6. In-Cell Western assay
HEKtau-CGFP cells were maintained in MEM (11095, Invitro-
gen), 10% FBS (10099, Invitrogen), 200 lg/ml geneticin (10131–
027, Invitrogen). Cells were plated in 96-well plates at 50000
cells/100 ll per well and incubated overnight. The following day
serial dilutions of ThiametG in media with a ﬁnal DMSO concentra-
tion of 0.5% or vehicle were added to the cells and incubated for
16 h. Cells were washed in PBS and 3.7% formaldehyde in PBS
was added for ﬁxation followed by permeabilization in 0.1% Triton
X-100 in PBS. After blocking for 1.5 h in LiCOR Odyssey blocking
buffer (927–40000, LiCOR Biosciences Inc.) at 22 C the cells were
probed with the Otau(S400) antibody at a concentration of 1 lg/
ml followed by detection with a goat anti-rabbit IRDye800CW anti-
body (926–32213, LiCOR Biosciences Inc.). The bound secondary
antibody was quantiﬁed on a LiCOR Odyssey infrared imager (Li-
COR Biosciences Inc.). For the pre-adsorption experiments the
Otau(S400) antibody was incubated with either 5 lg/ml O-GlcNAc
tau peptide (VYKSPVV-(O-GlcNAc)S-GDTSPRH) or 5 lg/ml ungly-
cosylated tau peptide (VYKSPVVSGDTSPRH) or 100 mM N-acetyl-
glucosamine (A8625, Sigma Aldrich) in LiCOR Odyssey blocking
Fig. 1. ELISA with BSA-conjugated O-GlcNAc tau and unglycosylated tau peptide
demonstrated highly speciﬁc binding activity of Otau(S400) for the O-GlcNAc-tau
peptide. EC50 for the O-GlcNAc tau peptide was 785 nM and lowest limit of
detection was at 1 ng/ml Otau(S400).
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were calculated using GraphPad Prism software.
2.7. ThiametG treatment of Tg21221, JNPL3 mice and tau knockout
mice
Tg21221 mice were generated as described elsewhere [10] and
bred at the McLaughlin Research Institute (MRI). 3 months old fe-
males and male Tg21221 (n = 15/group) were used. Eighteen
weeks old male JNPL3 mice were obtained from Taconic Farms
(NY, USA) and 16 weeks old male tau knockout mice (B6.129-
Mapttm1Hnd/J) were obtained from Jackson Laboratory (Bar Harbor
ME, USA). All experiments were approved by the EMD Serono Re-
search & Development Institute and MRI Institutional Animal Care
and Use Committees (IACUC). ThiametG was dissolved in water
and administered po at a concentration of 500 mg/kg/day for ﬁve
consecutive days in JNPL3 mice and for 1 or 14 consecutive days
in Tg21221 mice. ThiametG was administered at a single dose in
tau knockout mice. Water was used for the vehicle treated groups.
2.8. Brain lysis and tau immunoprecipitation
Animals were euthanized 4 h after administration of the last
dose of ThiametG. Hemi-forebrains were rapidly dissected and fro-
zen on dry ice. Tissue samples were homogenized in Phosphosafe
Buffer (71296–4, EMD Millipore), followed by centrifugation
(15000 g) to remove cellular debris. The ensuing supernatant
was assayed by DC protein assay (500–0113, 500–0114, 500–
0115, BioRad) to determine protein concentrations. Twenty micro-
grams of brain lysate were subjected to Western blotting as de-
scribed below. To immunoprecipitate tau protein from JNPL3
brain lysate a Crosslink Immunoprecipitation kit (26147, Thermo-
Scientiﬁc) was used according to the manufacturer’s instruction. In
brief, protein A/G resin was crosslinked to 20 lg of the tau-5 anti-
body (MS-247-P1, ThermoScientiﬁc). Two hundred and ﬁfty micro-
grams of brain lysates as described above was incubated with the
resin-coupled tau antibody overnight at 4 C. Samples were eluted
with 50 ll of low pH elution buffer and immediately neutralized
with 5 ll 1 M Tris, pH 9.5.
2.9. Western blotting
Protein samples were subjected to 4–20% Tris–glycine SDS–
PAGE (WT4121A, Invitrogen) for separation of cell lysate and to
4–15% Tris–HCl SDS–PAGE (345–0028, BioRad) for brain lysate, fol-
lowed by semi-dry transfer to nitrocellulose membranes (IB301–
01, Invitrogen). Membranes were blocked in LiCOR Odyssey block-
ing buffer (927–40000, LiCOR Biosciences Inc.), then incubated
with the appropriate primary antibody for 2 h at RT or overnight
at 4 C, extensively washed in TBST, followed by labeling with IR-
Dye680LT- or IRDye800CW-conjugated goat-anti-rabbit or -mouse
secondary antibody (926–68021, 926–32212, LiCOR Biosciences
Inc.) at a dilution of 1:10 000 for 1 h at RT. After extensive washing
in TBST membranes were scanned on the LiCOR Odyssey infrared
imager (LiCOR Biosciences Inc.). The following primary antibodies
and dilutions were used in this study: RL2 (MA1072, ThermoScien-
tiﬁc) at 1:200, tau-5 (MS-247-P1, ThermoScientiﬁc) at 1:5000, HT7
(MN1000, ThermoScientiﬁc) at 1:50000, and Otau(S400) at 1:1000.
3. Results
3.1. Speciﬁcity of Otau(S400) against tau peptide O-GlcNAcylated at
Ser400
In order to generate a rabbit monoclonal antibody against
O-GlcNAc modiﬁed tau at Ser400 two peptides spanning thesequence around Ser400 were synthesized, one of which carried
an O-GlcNAc moiety at serine 400: O-GlcNAc tau peptide
(cVYKSPVV-(O-GlcNAc)S-GDTSPRH) and unglycosylated tau pep-
tide (cVYKSPVVSGDTSPRH). Rabbits were immunized with KLH-
conjugated O-GlcNAc tau peptide by subcutaneous injections, fol-
lowed by splenocyte collection and hybridoma fusion. Positive
hybridoma clones identiﬁed by using a standard ELISA protocol
against BSA-conjugated O-GlcNAc tau peptide were further sub-
cloned. One ELISA positive hybridoma subclone was expanded
and protein A puriﬁed. The puriﬁed antibody was designated
Otau(S400). Antibody antigen binding activity testing by ELISA
against BSA-conjugated O-GlcNAc tau and unglycosylated tau pep-
tide showed that Otau(S400) has highly speciﬁc binding activity
with a calculated EC50 of 785 nM towards the O-GlcNAc-tau pep-
tide and was non-reactive to the unglycosylated peptide (Fig. 1).
The lowest O-GlcNAc tau peptide speciﬁc signal could be detected
at 1 ng/ml antibody concentration.
3.2. Speciﬁcity of Otau(S400) for O-GlcNAcylated tau in OGT
transfected cells
To further demonstrate the speciﬁcity of the Otau(S400) anti-
body in a cellular context we overexpressed His-tagged human
OGT in HEK293 cells stably expressing myc-DDK-tagged human
2N4R tau (HEKtau). Western blot analysis of cell lysate with an
antibody (RL2) that recognizes O-GlcNAc modiﬁcations on a broad
spectrum of proteins conﬁrmed that OGT was active when heterol-
ogously expressed in HEKtau cells as indicated by the stronger
intensity of bands in the OGT transfected as compared to mock
transfected cells (Fig. 2A). A similar increase in signal intensity
was observed in the parental HEK293 cell line in the presence of
OGT (Fig. 2A). When probed with the Otau(S400) antibody a strong
immunopositive band with an apparent molecular mass of
60 kDa was detected in OGT transfected, but not in mock trans-
fected HEKtau cells (Fig. 2A). This band overlapped with a band de-
tected with an antibody recognizing total tau (tau-5), suggesting
that Otau(S400) indeed recognized O-GlcNAcylated tau in cells. A
band with similar intensity was detected with the tau-5 antibody
in the mock transfected HEKtau cells conﬁrming equal loading of
protein lysates on the gel (Fig. 2A). Interestingly, the tau-5 anti-
body revealed a duplet of bands, of which only the band with lower
molecular mass co-localized with the Otau(S400) band (see over-
lay, Fig. 2A). This suggests that only a subpopulation of tau is sub-
strate for O-GlcNAcylation in HEKtau cells. As a further
demonstration of the antibody speciﬁcity, no immunoreactive
bands were observed with the Otau(S400) antibody in the absence
or presence of OGT in HEK293 cells that do not express tau
(Fig. 2A).
Fig. 2. (A) Western blot of lysates from HEKtau and HEK cells, OGT or mock transfected, and probed with antibodies against total O-GlcNAc levels (RL2), O-GlcNAc tau at
Ser400 (Otau(S400)) and total tau (tau-5). (B) Western blot of tau immunoprecipitated from lysates of OGT or mock transfected HEKtau cells and probed with antibodies
against O-GlcNAc tau at Ser400 (Otau(S400)) and total tau (tau-5).
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fected HEKtau cells represented O-GlcNAcylated tau we afﬁnity-
puriﬁed myc-DDK-tagged tau from OGT transfected HEKtau cells
via a FLAG antibody that recognizes the DDK epitope and subjected
it to Western blotting with the Otau(S400) antibody. A strong
immunoreactive band was observed at 60 kDa in the tau prepara-
tion isolated from OGT transfected HEKtau cells, but only a very
faint signal was seen in the tau preparation from mock transfected
HEKtau cells (Fig. 1B). Tau-5 staining conﬁrmed that the immuno-
precipitated proteins were indeed tau (Fig. 1B). Similar to our pre-
vious observation, Otau(S400) positive tau only overlapped with
the lower molecular mass tau (see overlay, Fig. 2B).
3.3. Speciﬁcity of Otau(S400) for O-GlcNAcylated tau in ThiametG
treated cells
OGT overexpression in cells may result in unphysiologically
high levels of protein O-GlcNAcylation. To demonstrate that
Otau(S400) can detect tau O-GlcNAcylation under more physiolog-
ical conditions cellular O-GlcNAcylation was increased by incubat-
ing HEKtau cells in the presence of the potent and selective OGA
inhibitor ThiametG [11]. ThiametG treatment elevated global pro-
tein O-GlcNAcylation in HEKtau and HEK cells as determined with
the RL2 antibody (Fig. 3A). Otau(S400) detected a band at 60 kDa
only in the ThiametG treated, but not vehicle treated HEKtau cells,
indicating that the antibody is sensitive enough to detect tau O-
GlcNAcylation at substoichiometric levels in cells (Fig. 3A). Fur-
thermore, this also demonstrates that tau is a substrate for endog-
enously expressed OGT in HEK cells. Bands with similar intensities
were detected with the tau-5 antibody in both, Thiamet G and
vehicle treated HEKtau cells, conﬁrming equal loading of protein
lysates on the gel (Fig. 3A). HEK293 cells that did not express tau
did not show any signiﬁcant immunoreactivity with Otau(S400)
with or without ThiametG treatment (Fig. 3A).In order to be able to rapidly identify small molecule OGA inhib-
itors that elevate tau O-GlcNAcylation at Ser400 a sensitive cellular
assay is needed that allows for high throughput screening of com-
pounds. To this end we employed an In-Cell Western assay plat-
form in which HEKtau-CGFP cells were treated with increasing
concentrations of Thiamet G (300 pM–30 lM; Fig. 3B) and O-Glc-
NAc tau was detected with the Otau(S400) antibody. Thiamet G in-
creased tau O-GlcNAcylation in a concentration dependent manner
with an EC50 of 10 nM. Importantly, adding 5 lg/ml O-GlcNAc tau
peptide during the primary antibody incubation completely abol-
ished the detection of O-GlcNAc tau, but no signiﬁcant change in
O-GlcNAc tau signal was seen in the presence of 5 lg/ml of the
unglycosylated version of the peptide (EC50 = 14.3 nM). Notably,
adding 100 mM free N-acetyl-glucosamine to the primary antibody
did not interfere with the detection of O-GlcNAc tau (EC50 = 12.7 -
nM). Taken together, this clearly indicates that the Otau(S400)
antibody requires the pendant O-GlcNAc residue as well as the
peptide backbone for binding (Fig. 3B).
3.4. Speciﬁcity of Otau(S400) for O-GlcNAcylated tau in ThiametG
treated Tg21221 and JNPL3 mice
Accumulating evidence suggests that increasing O-GlcNAc lev-
els in brain via the pharmacological inhibition of OGA may provide
a therapy for the treatment of Alzheimer’s disease and other tauop-
athies [2]. To establish that Otau(S400) recognizes O-GlcNAcylated
tau in vivo we employed two different tau transgenic animal mod-
els. First, we treated Tg21221 mice, a transgenic mouse line that
overexpresses human wild type tau (variant 0N4R), with 500 mg/
kg ThiametG for 1 or 14 days [10]. To demonstrate that oral Thia-
metG administration is effective in increasing O-GlcNAc levels in
brain we probed brain lysate from singly and repeatedly treated
animals with the RL2 antibody. A single dose of ThiametG slightly
increased global protein O-GlcNAcylation as compared to vehicle
Fig. 3. (A) Western blot of lysates from HEKtau and HEK cells treated with 10 lM ThiametG and probed with antibodies against total O-GlcNAc levels (RL2), O-GlcNAc tau at
Ser400 (Otau(S400)) and total tau (tau-5). (B) In-Cell Western assay of HEKtau-CGFP cells treated with ThiametG (300 pM–30 lM) and detected with Otau(S400) in the
absence (no competition) or presence of O-GlcNAc tau peptide (5 lg/ml), unglycosylated tau peptide (5 lg/ml) or 100 mM free GlcNAc. The graph depicts a ThiametG
concentration dependent increase of cellular O-GlcNAc tau (no competition, EC50 = 10 nM), with unglycosylated tau peptide (EC50 = 14.3 nM), with free GlcNAc
(EC50 = 12.7 nM), but no signal in the presence of O-GlcNAc tau peptide.
Fig. 4. (A) Western blot of lysates from Tg21221 mice treated with 500 mg/kg ThiametG or vehicle for 1 or 14 days and probed with antibodies against total O-GlcNAc levels
(RL2), O-GlcNAc tau at Ser400 (Otau(S400)) and total tau (HT7). The graph depicts an increase in O-GlcNAc tau signal in response to 14 doses of ThiametG. (B) Western blot of
lysates and immunoprecipitated tau from JNPL3 mice treated with 500 mg/kg ThiametG or vehicle for 5 days and probed with antibodies against total O-GlcNAc levels (RL2),
O-GlcNAc tau at Ser400 (Otau(S400)) and total tau (HT7). The graph depicts an increase in O-GlcNAc tau signal after 5 daily doses of ThiametG.
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sulted in a robust increase in global protein O-GlcNAcylation
(Fig. 4A). A single dose of ThiametG did not signiﬁcantly increase
tau O-GlcNAcylation at Ser400 as compared to vehicle treated ani-
mals (Fig. 4A). However, two weeks of daily administration of Thi-
ametG elicited a signiﬁcant ninefold increase in signal with the
Otau(S400) antibody, indicating that subchronic OGA inhibitionstrongly increases O-GlcNAc modiﬁcations on human wild type
tau that can be detected with the Otau(S400) antibody (Fig. 4A).
The overlay showed a partial overlap of O-GlcNAcylated tau with
total tau, suggesting that only a subspecies of tau is subject to O-
GlcNAcylation in this treatment paradigm.
Tg21221 mice do not exhibit the typical tau pathology that can
be observed in JNPL3 mice, a widely used transgenic mouse model
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the P301L mutant form of tau [12]. To demonstrate that
Otau(S400) can recognize O-GlcNAc tau in this mouse model JNPL3
mice were treated with 500 mg/kg ThiametG or vehicle daily for
ﬁve days. Subchronic treatment with ThiametG elicited a robust in-
crease in global protein O-GlcNAcylation as detected with the RL2
antibody (Fig. 4B). Similar to Tg21221 mice, we observed a highly
signiﬁcant ninefold increase in O-GlcNAc tau signal as compared
to vehicle treated animals. To conﬁrm that the Otau(S400) immu-
nopositive bands represented tau we immunoprecipitated tau
from JNPL3 brain lysate with the tau-5 antibody and subjected it
to Western blotting with the Otau(S400) antibody. Strong immu-
noreactive bands were observed around 50 kDa in the tau prepa-
ration isolated from ThiametG treated mouse brain, but a much
fainter signal was seen the tau preparation from vehicle treated
animals (Fig. 4B). Staining with the HT7 antibody that recognizes
human tau conﬁrmed that the immunoprecipitated proteins were
indeed tau (Fig. 4B).
Lastly, to demonstrate the low cross-reactivity of the
Otau(S400) antibody with other O-GlcNAcylated proteins we
probed brain lysates from tau knockout mice (tau KO) that were
treated with a single dose of 500 mg/kg ThiametG po or vehicle
with the Otau(S400) antibody (Fig. 5). A very faint signal could
be seen at 50, 130 kDa and at the top of the gel only after scan-
ning the Western blot at highest sensitivity, indicating that the
Otau(S400) antibody shows only limited cross-reactivity with
other O-GlcNAcylated proteins unrelated to tau. Tau-5 antibody
staining revealed no signal, conﬁrming that tau was absent in
brains of tau KO mice (Fig. 5)
Taken together, this suggests that Otau(S400) is a valid tool to
study changes in tau O-GlcNAcylation at Ser400 in mouse models
of tauopathy.
4. Discussion
O-GlcNAcylation is a ubiquitous posttranslational modiﬁcation
that has been implicated in a multitude of vital cellular processes
including transcriptional regulation, cell signaling and proteasomal
degradation [13]. O-GlcNAc is also found on many cytoskeletal
proteins. Although O-GlcNAcylation of proteins emerges as being
as abundant as phosphorylation [14], the former has by far not
as intensely studied than the latter. This is partly due to the rela-
tive paucity of research tools that allow for the speciﬁc analysisFig. 5. Western blot of lysates from tau KO mice treated with a single dose of
500 mg/kg ThiametG or vehicle and probed with antibodies against O-GlcNAc tau at
Ser400 (Otau(S400) and total tau (tau-5).of this modiﬁcation on proteins of interest. Recent years have
brought forward the development of elegant biochemical methods
to sensitively label and identify O-GlcNAcylated proteins [15,16].
However, these methods are based on the enrichment of a pool
of O-GlcNAcylated proteins that require additional biochemical
methods to subsequently determine the identity of the O-GlcNAc
modiﬁed protein. The availability of epitope speciﬁc antibodies
that unambiguously recognize O-GlcNAc moieties on a speciﬁc
protein of interest is limited. Earlier attempts to generate O-Glc-
NAc-site speciﬁc antibodies for individual proteins have resulted
in antibodies that recognize O-GlcNAc modiﬁcations on many pro-
teins in a relatively peptide-independent manner [17,18]. More re-
cently, a polyclonal rabbit antibody recognizing the neuronal
protein tau when O-GlcNAcylated at Ser400, termed 3925, has
been described [7]. While the authors were able to clearly demon-
strate that 3925 recognizes recombinant O-GlcNAc tau in vitro, the
antibody showed strong cross-reactivity with other proteins in rat
brain lysates limiting its use for in vivo studies. Here we describe
the generation of a new rabbit monoclonal antibody, named
Otau(S400), that is speciﬁc for human tau O-GlcNAcylated at
Ser400. Our antibody showed high binding afﬁnity for a tau pep-
tide O-GlcNAc modiﬁed at Ser400 by ELISA and only recognized a
single band corresponding to tau in cells in which O-GlcNAcylation
was increased either by overexpression of OGT or by pharmacolog-
ical treatment with the OGA inhibitor ThiametG. Furthermore, in
tau transgenic animal models expressing either wild type or mu-
tant tau Otau(S400) showed strong immunoreactivity for O-Glc-
NAc tau in response to treatment with ThiametG, but not in
vehicle treated animals. Binding of Otau(S400) to O-GlcNAcylated
tau could be completely abolished with a tau peptide O-GlcNAcy-
lated at Ser400, but not with the unmodiﬁed version of the same
peptide or with free N-acetyl-glucosamine. This observation is in
good agreement with a number of studies of O-GlcNAc epitope
speciﬁc antibodies that show no or incomplete competition with
free GlcNAc [19,20,7]. This strongly suggests that Otau(S400) spe-
ciﬁcally recognizes the O-GlcNAc moiety at Ser400 in the context
of the tau peptide backbone and is consistent with the minimal
cross-reactivity of Otau(S400) in brain lysate of tauKO mice. In
summary, these data highlight the power of this new antibody
for the investigation of tau O-GlcNAcylation at Ser400 in a cellular
or tissue context.
Tau is a major constituent of neuroﬁbrillary tangles, a charac-
teristic pathological feature of Alzheimer’s disease and other tau-
opathies [1]. Neuroﬁbrillary tangle formation involves
aggregation and hyperphosphorylation of tau in neurons, ulti-
mately leading to neuronal cell death. Intense research efforts have
been made to elucidate mechanisms of tau aggregation in order to
identify molecular drug targets to interfere with tau aggregation.
Recent data support a role for O-GlcNAcylation in stabilizing tau
against aggregation [2]. While the exact mechanism by which O-
GlcNAcylation may protect tau from aggregating remains to be
determined, it is feasible that O-GlcNAc moieties impose a confor-
mation on tau that makes it less prone to aggregation. Notably, O-
GlcNAc modiﬁcation at Ser400 appears to play an important role in
inhibiting tau oligomerization in vitro [2] and an increase in tau O-
GlcNAcylation at Ser400 correlated with a reduction in tau pathol-
ogy and slowed neurodegeneration in a mouse model of tauopathy
[2]. It is thus important to be able to monitor changes in tau O-Glc-
NAcylation at Ser400 in response to genetic or pharmacological
manipulation to understand its role in tau function. With the
Otau(S400) antibody we have established a tool that can readily
detect changes in tau O-GlcNAcylation at this epitope in vitro
and in vivo as demonstrated in two tau transgenic models, JNPL3
and Tg21221 mice. This will greatly facilitate the understanding
of the role of O-GlcNAcylation in tau aggregation and the discovery
of efﬁcacious drugs aimed at increasing O-GlcNAcylation of tau.
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